Creo Medical Group PLC Appointment of Marco Scarci
June 22 2023 - 1:00AM
RNS Non-Regulatory
TIDMCREO
Creo Medical Group PLC
22 June 2023
Creo Medical Group plc
("Creo" the "Company" or the "Group")
Appointment of Marco Scarci to lead Pulmonary Clinical Advisory
Group
Group to help shape and take forward Creo's MicroBlate(TM)
clinical strategy
Creo Medical Group plc (AIM: CREO), the medical device company
focused on the emerging field of surgical endoscopy, announces that
it has appointed Marco Scarci as lead of the Company's newly
created Pulmonary Clinical Advisory Group.
Marco Scarci, who will provide expert clinical advice and
counsel in relation to the Company's microwave ablation technology,
is a highly experienced London-based Consultant Thoracic Surgeon,
specialising in minimally invasive techniques. His specialist
training took place in Italy, Malta, the Essex Cardiothoracic
Centre and Guy's and St Thomas', London. Following a six-month
fellowship in minimally invasive surgery at the University of
Toronto, Canada, Mr Scarci was appointed Consultant Thoracic
Surgeon at Papworth Hospital NHS Foundation Trust, Cambridge.
Marco joins Creo as it looks to develop and build on clinical
trials to assess the safe and effective ablation of pre-cancerous
and cancerous lesions through the Company's MicroBlate(TM)
products. Marco's extensive network will enable him to engage with
Kamaptive partners, medical advisors, key opinion leaders and
medical societies to help shape and take forward Creo's microwave
ablation clinical strategy, with a view to maximising the impact
the technology can have on patients around the world.
Marco Scarci said of his appointment: "I'm delighted to join
Creo Medical and to help shape an ablation clinical strategy with
the aim of demonstrating what I and many others believe this
technology to be - a potential game changer in the way soft tissue
lesions can be treated in future."
Craig Gulliford, Chief Executive Officer of Creo Medical, added
"We welcome Marco's vast clinical experience to the team. With one
clinical trial for our lung ablation technology already under way
and further trials in the pipeline, it's fantastic to have such a
globally respected mind helping guide us as we look to maximise the
impact of our technology and achieve the best possible outcomes for
patients across multiple indications."
Enquiries:
Creo Medical Group plc www.creomedical.com
Richard Rees (CFO) +44 (0)1291 606 005
Cenkos Securities plc +44 (0)20 7397 8900
Stephen Keys / Camilla Hume (NOMAD)
Michael Johnson / Russell Kerr (Joint
Broker)
Numis Securities Limited (Joint
Broker) +44 (0)20 7260 1000
Freddie Barnfield / Duncan Monteith
/ Euan Brown
Walbrook PR Ltd Tel: + 44 ( 0)20 7933 8780 or creo@walbrookpr.com
Paul McManus / Sam Allen Mob: +44 (0)7980 541 893 / +44 (0)7502
/ Phillip Marriage 558 258 / +44 (0)7867 984 082
About Creo Medical
Creo Medical is a medical device company focused on the
development and commercialisation of minimally invasive
electrosurgical devices, bringing advanced energy to endoscopy.
The Company's vision is to improve patient outcomes through the
development and commercialisation of a suite of electrosurgical
medical devices, each enabled by CROMA, powered by Kamaptive. The
Group has developed the CROMA powered by Kamaptive full-spectrum
adaptive technology to optimise surgical capability and patient
outcomes. Kamaptive is a seamless, intuitive integration of
multi-modal energy sources, optimised to dynamically adapt to
patient tissue during procedures such as resection, dissection,
coagulation and ablation of tissue. Kamaptive technology provides
clinicians with increased flexibility, precision and controlled
surgical solutions. CROMA currently delivers bipolar radiofrequency
("RF") energy for precise localised cutting and focused high
frequency microwave ("MW") energy for controlled coagulation and
ablation via a single accessory port. This technology, combined
with the Group's range of patented electrosurgical devices, is
designed to provide clinicians with flexible, accurate and
controlled clinical solutions. The Directors believe the Company's
technology can impact the landscape of surgery and endoscopy by
providing a safer, less-invasive and more cost-efficient option for
procedures.
For more information, please refer to the website
www.creomedical.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRADGGDLDGDDGXB
(END) Dow Jones Newswires
June 22, 2023 02:00 ET (06:00 GMT)
Creo Medical (LSE:CREO)
Historical Stock Chart
From Apr 2024 to May 2024
Creo Medical (LSE:CREO)
Historical Stock Chart
From May 2023 to May 2024